{"gene":"AHR","run_date":"2026-06-09T22:02:42","timeline":{"discoveries":[{"year":2003,"finding":"Ligand-bound AHR translocates from cytoplasm to nucleus, dissociates from Hsp90, and heterodimerizes with ARNT; the AHR/ARNT heterodimer binds XRE (xenobiotic response elements) in the promoter of target genes such as CYP1A1 to drive their transcription.","method":"Mechanistic studies of CYP1A1 induction; ligand binding, nuclear translocation, and DNA-binding assays","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Strong — canonical mechanism established by multiple labs across decades; replicated in numerous independent studies","pmids":["12573486"],"is_preprint":false},{"year":2001,"finding":"In the cytoplasm, AHR interacts with Hsp90 and the immunophilin chaperone AIP (AhR-interacting protein) for proper folding and ligand-binding competence; after nuclear entry, agonist-activated AHR is degraded via the ubiquitin–26S proteasome pathway, limiting the duration of transcriptional activation.","method":"Biochemical characterization, proteasome inhibition experiments, receptor turnover assays","journal":"Current drug metabolism","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods, independently replicated across labs","pmids":["11469723"],"is_preprint":false},{"year":2000,"finding":"AIP binds to AHR in an Hsp90-dependent manner: AIP binds the C-terminus of Hsp90 via its tetratricopeptide repeat domain (mutation K266A abolishes Hsp90 binding and reduces AHR binding by 75–80%), while the alpha-helical C-terminus of AIP is absolutely required for AHR interaction but not for Hsp90 binding. Hsp90 is required for AHR–AIP complex formation.","method":"Reticulocyte lysate binding assays, site-directed mutagenesis, geldanamycin/ATP sensitivity tests, deletion analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution in reticulocyte lysate with mutagenesis, single lab but multiple orthogonal methods","pmids":["10961990"],"is_preprint":false},{"year":2008,"finding":"Ligand-activated AHR assembles a CUL4B-based E3 ubiquitin ligase complex (CUL4B^AHR), in which AHR acts as a substrate-recognition subunit to recruit estrogen receptor α (ERα) and androgen receptor (AR) for ubiquitin-mediated proteolysis, defining a non-transcriptional role for AHR as a ligand-dependent E3 ubiquitin ligase.","method":"Co-immunoprecipitation, ubiquitination assays, proteasome-dependent degradation assays","journal":"Biochemical pharmacology","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — co-IP and functional ubiquitination assays; single lab but multiple orthogonal methods","pmids":["18838062"],"is_preprint":false},{"year":2008,"finding":"AHR possesses a functional nuclear localization signal (NLS) and a nuclear export signal (NES); phosphorylation of residues near these signals controls AHR's distribution between cytoplasm and nucleus. Cell density modulates both AHR intracellular localization and its transactivation of target genes including the transcriptional repressor Slug.","method":"Subcellular fractionation, live-cell imaging, phosphorylation studies, NLS/NES mutagenesis","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct localization experiments with functional consequence, single lab","pmids":["18983832"],"is_preprint":false},{"year":2001,"finding":"AHR and HIF-1α signaling pathways mutually repress each other by competing for the shared partner ARNT: TCDD-activated AHR reduced hypoxia-inducible reporter activity, and hypoxia-mimicking agents reduced AHR-mediated CYP1A1 activity and DRE-binding; the interaction is attributable to changes in DNA-binding activity at DRE and HIF-1 binding sites.","method":"Reporter gene assays, EMSA (DNA-binding assays), enzyme activity assays in multiple cell lines","journal":"Environmental toxicology and pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple cell lines and orthogonal readouts; single study","pmids":["11382553"],"is_preprint":false},{"year":2008,"finding":"AHR agonists increase MMP-1 expression in bronchial epithelial cells via a non-canonical AHR pathway: AHR agonists elevate cytosolic calcium, activating CaMKII, which activates MAPK pathways, phosphorylating c-Jun, c-Fos, and ATF-2, which bind AP-1 elements in the MMP-1 promoter; upregulated MMP-1 further activates MMP-2 and MMP-9.","method":"Reporter assays, pharmacological inhibitors, kinase activity assays, ChIP-like promoter analysis","journal":"Journal of molecular medicine (Berlin, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pathway inhibitors and orthogonal readouts, single lab","pmids":["24469321"],"is_preprint":false},{"year":2017,"finding":"Constitutive expression of Cyp1a1 in mice depletes endogenous AHR ligands, generating a quasi-AHR-deficient state with loss of AHR-dependent ILC3 and Th17 cells and increased susceptibility to enteric infection, demonstrating that CYP1A1 enzymes act as a feedback mechanism regulating AHR ligand availability in vivo.","method":"Transgenic mouse model (constitutive Cyp1a1 expression throughout body or restricted to intestinal epithelium), immune cell phenotyping, infection challenge","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic mouse model with specific phenotypic readout and dietary rescue, published in Nature","pmids":["28146477"],"is_preprint":false},{"year":2020,"finding":"IL4I1 (interleukin-4-induced-1) activates AHR through generation of indole metabolites and kynurenic acid from tryptophan catabolism, promoting cancer cell motility and suppression of adaptive immunity.","method":"Pan-tissue AHR signature analysis, biochemical assays of IL4I1 metabolite production, mouse model of CLL with IL4I1 manipulation","journal":"Cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical pathway and in vivo mouse model, single study","pmids":["32818467"],"is_preprint":false},{"year":2023,"finding":"Cryo-EM structures of the Hsp90–AHR–p23 complex (with or without XAP2) resolved the mouse AHR PAS-B domain; a highly conserved 'bridge motif' of AHR is responsible for interaction with the Hsp90 dimeric lumen; ligand-free AHR PAS-B is stabilized by XAP2 binding; conserved DE-loop residues and pocket inner residues are important for ligand binding.","method":"Cryo-EM structure determination, mutagenesis, protein purification","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — cryo-EM structure with mutagenesis validation, single study","pmids":["36649707"],"is_preprint":false},{"year":2021,"finding":"AHR regulates NK cell migration via transcriptional induction of ASB2, which promotes ubiquitin-mediated degradation of filamin A; loss of AHR reduces ASB2 expression, stabilizes filamin A, and impairs NK cell migration and tumor infiltration in vivo.","method":"Ahr-/- mouse model, gene expression analysis, AHR agonist treatment, ASB2 knockdown, filamin A degradation assays, in vivo tumor migration assay","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO and knockdown with mechanistic pathway placement, single lab","pmids":["33717133"],"is_preprint":false},{"year":2022,"finding":"AHR activation in keratinocytes promotes SIRT1-dependent differentiation by repressing glycolysis: AHR binds and reduces expression of the glucose transporter SLC2A1 and glycolytic enzyme ENO1, lowering glucose uptake and ATP; this metabolic shift increases SIRT1 protein levels in a pyruvate-dependent manner, and SIRT1 is required for AHR-induced keratinocyte differentiation.","method":"ChIP, qPCR, metabolic assays (glucose uptake, pyruvate/lactate), protein level measurements, pharmacological inhibitors, SIRT1 loss-of-function","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and multiple orthogonal metabolic and functional assays, single lab","pmids":["30393078"],"is_preprint":false},{"year":2019,"finding":"AHR loss-of-function in Ahr-/- mice causes dysregulation of Notch and ERα signaling: reduced expression of Notch1, Notch3, and their target HES1 leads to early spermatocyte maturation and depletion of spermatids (reduced fertility); meanwhile, absence of AHR in the mammary fat pad leads to overexpression of ERα and enhanced ductal growth.","method":"Ahr-/- mouse model, gene expression analysis, histology, serum hormone measurements","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with specific phenotypic readouts, single lab","pmids":["27688768"],"is_preprint":false},{"year":2017,"finding":"AHR exerts a cell-cycle regulatory, tumor-suppressive function in pituitary cells independent of exogenous ligand: AHR overexpression in GH3 cells reduced E2F-driven transcription, altered cell cycle regulator gene expression, and increased G0/G1 fraction; co-immunoprecipitation confirmed AHR–retinoblastoma protein (Rb1) interaction as the functional mechanism.","method":"AHR overexpression, siRNA knockdown, co-immunoprecipitation (AHR–Rb1), cell cycle analysis, qPCR","journal":"Endocrine-related cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP with functional cell cycle readouts, gain- and loss-of-function, single lab","pmids":["28649092"],"is_preprint":false},{"year":2021,"finding":"AHR is activated by coronavirus infection (including SARS-CoV-2); pharmacological inhibition of AHR suppressed HCoV-229E and SARS-CoV-2 replication in vitro, and single-cell RNA-seq from COVID-19 patients detected increased AHR and AHR target gene expression in infected lung epithelial cells.","method":"In vitro viral replication assay with AHR inhibitors, single-cell RNA-seq analysis of patient lung tissue","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro functional assay and patient scRNA-seq, single lab","pmids":["34446714"],"is_preprint":false},{"year":2021,"finding":"AHR is required for AFB1 (aflatoxin B1) toxicity in hepatocytes: AHR-deficient cells tolerated high AFB1 concentrations with significantly decreased AFB1-DNA adduct formation; AFB1 directly binds the N-terminus of AHR triggering nuclear translocation; AHR mediates P450 enzyme expression induced by AFB1.","method":"Genome-wide CRISPR-Cas9 screen, AHR-knockout cell lines, AFB1-DNA adduct quantification, nuclear translocation assay","journal":"Signal transduction and targeted therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR screen and mechanistic follow-up in AHR-KO cells, single study","pmids":["34373448"],"is_preprint":false},{"year":2023,"finding":"In lung endothelial cells, AHR is highly active and protects against influenza-induced vascular leakage by engaging tissue-protective transcriptional networks including the vasoactive apelin-APJ peptide system; endothelial-specific AHR deletion exacerbates lung damage and promotes apoptosis of airway epithelial cells.","method":"Endothelial-specific AHR conditional knockout mouse model, lung permeability assays, influenza infection, transcriptomic analysis","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type specific genetic KO with defined mechanistic pathway in Nature","pmids":["37587341"],"is_preprint":false},{"year":2023,"finding":"AHR acts as a critical node for endothelial sensing of dietary metabolites in the intestine; AHR-mediated signaling in endothelial cells promotes cellular quiescence, vascular normalcy, and restrains inflammatory responses; endothelial AHR deficiency results in dysregulated inflammatory responses and initiation of proliferative pathways; endothelial AHR sensing of dietary ligands is required for protection against enteric infection.","method":"Single-cell endothelial atlas, endothelial-specific AHR conditional knockout, transcriptomic analysis, infection challenge","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-type specific genetic KO with scRNA-seq and functional infection readout, published in Nature","pmids":["37586410"],"is_preprint":false},{"year":2022,"finding":"UVB-generated DNA damage activates AHR, which cooperates with SP1 to induce MMP2 and MMP11 expression (but not MMP1/3) in keratinocytes; topical AHR antagonists (vitamin B12 and folic acid) ameliorate UVB-induced wrinkle formation in mice while reducing MMP2 expression.","method":"Mechanistic studies in HaCaT keratinocytes with AHR/SP1 pathway inhibition/knockdown, reporter assays, mouse wrinkle model with topical antagonists","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic cell studies with in vivo validation, single lab","pmids":["35316219"],"is_preprint":false},{"year":2019,"finding":"Homozygous stop-gain mutation (p.Q621*) in AHR causes autosomal recessive foveal hypoplasia and infantile nystagmus in humans; AHR loss-of-function in Ahr-/- mice impairs optic nerve myelin sheath formation and produces conjugate horizontal pendular nystagmus, identifying AHR as a physiological regulator of myelination.","method":"Whole exome sequencing (human), Ahr-/- mouse model, optic nerve histology","journal":"Brain : a journal of neurology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetic finding corroborated by mouse KO phenotype with histological mechanistic readout","pmids":["31009037"],"is_preprint":false},{"year":2017,"finding":"AHR deficiency in mice leads to demyelinating disease: Ahr-/- optic nerves show altered lipid composition of the myelin sheath and decreased expression of myelin-associated glycoprotein (MAG), accompanied by increased pro-inflammatory cytokines; inflammation is causally linked to AHR-dependent decreased MAG expression.","method":"Ahr-/- mouse model, lipid analysis, immunostaining for MAG, cytokine expression profiling","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with specific molecular and histological readouts, single lab","pmids":["28851966"],"is_preprint":false},{"year":2008,"finding":"cAMP-dependent protein kinase (PKA) can render AHR nuclear and activate AHR-sensitive genes through a mechanism fundamentally different from exogenous ligand-driven nuclear entry, indicating a ligand-independent mode of AHR activation.","method":"PKA activation/inhibition studies, nuclear import assays","journal":"Biochemical pharmacology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, mechanistic follow-up limited; abstract does not fully describe experimental methods","pmids":["19013136"],"is_preprint":false},{"year":2023,"finding":"Tryptophan deprivation sensitizes the AHR pathway by inducing AHR overexpression (independent of kynurenine but triggered by tryptophan depletion itself) and by increasing cellular kynurenine uptake via GCN2-dependent upregulation of the transporter LAT1 (SLC7A5), so that normally weak AHR agonists such as kynurenine potently activate AHR target genes and potentiate Treg differentiation.","method":"RT-qPCR, western blot, Ahr allele variant mouse T cells, Ahr knockout T cells, in vitro Treg differentiation assay","journal":"Journal for immunotherapy of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods and genetic models, single lab","pmids":["37344101"],"is_preprint":false},{"year":2024,"finding":"In MerTK+ tumor-associated macrophages, AHR transcriptionally induces ALKAL1, which facilitates MerTK phosphorylation, resulting in heightened phagocytic activity and polarization toward an immunosuppressive phenotype; targeted delivery of an AHR antagonist to tumor-associated macrophages suppressed MerTK expression and improved anti-PD-L1 therapy efficacy.","method":"scRNA-seq, mechanistic studies with AHR antagonist, adoptive macrophage transfer, targeted nanoparticle delivery in vivo","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — mechanistic studies with in vivo validation, single lab","pmids":["39365866"],"is_preprint":false}],"current_model":"AHR is a cytoplasmic, ligand-activated transcription factor of the bHLH-PAS family that, upon ligand binding, dissociates from its Hsp90–AIP–p23 chaperone complex (structurally resolved by cryo-EM), translocates to the nucleus via a regulated NLS/NES phosphorylation mechanism, heterodimerizes with ARNT, and binds XRE sequences to drive transcription of target genes (CYP1A1, CYP1B1, etc.); activated nuclear AHR is subsequently degraded by the ubiquitin–26S proteasome pathway. Beyond canonical transcription, AHR assembles a CUL4B E3 ubiquitin ligase complex to promote proteolysis of ERα and AR, regulates NK cell migration through ASB2-mediated filamin A degradation, controls keratinocyte differentiation by repressing glycolysis and raising SIRT1, engages the apelin-APJ system to protect lung endothelial barrier integrity, and physiologically regulates optic nerve myelination—all functions revealed by genetic loss-of-function models and mechanistic biochemical studies."},"narrative":{"mechanistic_narrative":"AHR is a ligand-activated bHLH-PAS transcription factor that links sensing of xenobiotic and endogenous small molecules to a broad transcriptional program governing detoxification, tissue homeostasis, and immunity [PMID:12573486, PMID:28146477]. In the unliganded state AHR resides in the cytoplasm within a chaperone complex with Hsp90 and the immunophilin AIP/XAP2; AIP docks onto the Hsp90 C-terminus through its tetratricopeptide-repeat domain and contacts AHR through its alpha-helical C-terminus, stabilizing the ligand-binding-competent PAS-B domain [PMID:11469723, PMID:10961990, PMID:36649707]. Cryo-EM of the Hsp90–AHR–p23 complex resolved a conserved AHR 'bridge motif' that inserts into the Hsp90 dimeric lumen and showed that XAP2 stabilizes ligand-free PAS-B, with DE-loop and pocket residues forming the ligand-binding cavity [PMID:36649707]. Upon ligand binding AHR translocates to the nucleus—a redistribution controlled by phosphorylation near its NLS/NES—dissociates from Hsp90, heterodimerizes with ARNT, and binds xenobiotic response elements to drive transcription of CYP1A1 and other targets, after which nuclear AHR is degraded by the ubiquitin–26S proteasome to limit signaling duration [PMID:12573486, PMID:11469723, PMID:18983832]. The CYP1A1 enzymes it induces in turn deplete endogenous ligands, forming a feedback loop that sets AHR activity in vivo [PMID:28146477], and AHR activity is further tuned by competition with HIF-1α for shared ARNT and by ligand supply from tryptophan-catabolizing pathways such as IL4I1 [PMID:11382553, PMID:32818467]. Beyond canonical transcription, ligand-activated AHR serves as the substrate-recognition subunit of a CUL4B E3 ubiquitin ligase that targets ERα and AR for proteolysis [PMID:18838062]. Across tissues AHR executes protective and differentiation programs: it sustains intestinal ILC3/Th17 immunity [PMID:28146477], drives NK cell migration via ASB2-mediated filamin A degradation [PMID:33717133], promotes SIRT1-dependent keratinocyte differentiation by repressing glycolytic genes SLC2A1 and ENO1 [PMID:30393078], and in endothelium senses dietary metabolites to maintain vascular quiescence and barrier integrity, engaging the apelin-APJ system to protect against influenza- and infection-induced damage [PMID:37587341, PMID:37586410]. A homozygous stop-gain mutation (p.Q621*) in AHR causes autosomal recessive foveal hypoplasia and infantile nystagmus, and AHR-null mice show defective optic nerve myelination, establishing AHR as a physiological regulator of myelination [PMID:31009037, PMID:28851966].","teleology":[{"year":2000,"claim":"Established how AHR is held in a ligand-competent state, defining the architecture of the cytoplasmic chaperone complex through which AHR is folded and primed.","evidence":"Reticulocyte-lysate binding assays with AIP/Hsp90 mutagenesis and geldanamycin/ATP sensitivity tests","pmids":["10961990"],"confidence":"High","gaps":["Stoichiometry and dynamics of the full complex in cells not resolved","Did not show how ligand binding triggers complex dissociation"]},{"year":2001,"claim":"Resolved the lifecycle of AHR signaling — cytoplasmic chaperoning for ligand competence followed by proteasomal degradation of activated nuclear receptor — establishing that signal duration is actively limited.","evidence":"Biochemical characterization, proteasome inhibition, and receptor turnover assays","pmids":["11469723"],"confidence":"High","gaps":["E3 ligase responsible for activated-AHR turnover not identified here","Coupling between transcription and degradation not mechanistically dissected"]},{"year":2001,"claim":"Showed that AHR and HIF-1α are not independent pathways but compete for the shared dimerization partner ARNT, explaining crosstalk between xenobiotic and hypoxic signaling.","evidence":"Reporter assays, EMSA at DRE/HIF-1 sites, and enzyme activity assays across multiple cell lines","pmids":["11382553"],"confidence":"Medium","gaps":["Whether competition occurs at ARNT abundance or DNA-binding step not fully separated","In vivo physiological relevance not addressed"]},{"year":2003,"claim":"Consolidated the canonical mechanism: ligand-triggered nuclear translocation, Hsp90 dissociation, ARNT heterodimerization, and XRE-driven transcription of CYP1A1.","evidence":"Mechanistic CYP1A1 induction studies with ligand binding, translocation, and DNA-binding assays","pmids":["12573486"],"confidence":"High","gaps":["Full set of physiological target genes not enumerated","Tissue-specific cofactor requirements not defined"]},{"year":2008,"claim":"Revealed a non-transcriptional function: ligand-activated AHR assembles a CUL4B E3 ligase and acts as a substrate-recognition subunit to degrade ERα and AR, uncoupling AHR action from DNA binding.","evidence":"Co-immunoprecipitation, ubiquitination, and proteasome-dependent degradation assays","pmids":["18838062"],"confidence":"High","gaps":["Determinants of substrate selection by the AHR-CUL4B complex not mapped","Physiological contexts where this dominates over transcription unclear"]},{"year":2008,"claim":"Mapped how AHR subcellular distribution is set, showing phosphorylation near NLS/NES and cell density control localization and target gene transactivation.","evidence":"Subcellular fractionation, live-cell imaging, NLS/NES mutagenesis, and phosphorylation studies","pmids":["18983832"],"confidence":"Medium","gaps":["Kinases acting on the NLS/NES not all identified","Quantitative contribution relative to ligand-driven import unclear"]},{"year":2008,"claim":"Identified a non-canonical AHR signaling arm in which agonists drive MMP-1 expression through calcium/CaMKII/MAPK and AP-1 rather than XRE binding.","evidence":"Reporter assays, pharmacological inhibitors, and kinase activity assays in bronchial epithelial cells","pmids":["24469321"],"confidence":"Medium","gaps":["Whether AHR protein directly initiates the calcium signal is not established","In vivo relevance to airway remodeling untested"]},{"year":2008,"claim":"Provided evidence for ligand-independent activation, with PKA rendering AHR nuclear and activating target genes by a route distinct from exogenous ligand.","evidence":"PKA activation/inhibition studies and nuclear import assays","pmids":["19013136"],"confidence":"Low","gaps":["Single lab with limited mechanistic follow-up; molecular target of PKA on AHR not defined","Physiological trigger for this mode unknown"]},{"year":2017,"claim":"Demonstrated in vivo that CYP1A1 enzymes form a feedback loop depleting endogenous AHR ligands, linking AHR ligand availability to intestinal ILC3/Th17 immunity and infection resistance.","evidence":"Transgenic mice with constitutive or intestinal Cyp1a1, immune phenotyping, infection challenge, dietary rescue","pmids":["28146477"],"confidence":"High","gaps":["Identity of the depleted endogenous ligands not fully defined","Tissue-by-tissue ligand turnover not quantified"]},{"year":2017,"claim":"Showed a ligand-independent, tumor-suppressive AHR function through direct interaction with Rb1 to restrain E2F-driven cell cycle progression.","evidence":"Overexpression/knockdown, AHR–Rb1 co-IP, and cell cycle analysis in pituitary GH3 cells","pmids":["28649092"],"confidence":"Medium","gaps":["Reciprocal validation and structural basis of AHR–Rb1 binding lacking","Generality beyond pituitary cells untested"]},{"year":2017,"claim":"Linked AHR to myelin biology, showing AHR-deficient optic nerves have altered myelin lipid composition and reduced MAG with inflammation.","evidence":"Ahr-/- mice with lipid analysis, MAG immunostaining, and cytokine profiling","pmids":["28851966"],"confidence":"Medium","gaps":["Direct AHR target genes driving myelination not identified","Cell-autonomous versus inflammatory contributions not separated"]},{"year":2019,"claim":"Established AHR as a human disease gene, with a stop-gain mutation causing recessive foveal hypoplasia/nystagmus and mouse knockouts confirming a physiological role in optic nerve myelination.","evidence":"Whole exome sequencing in humans plus Ahr-/- mouse optic nerve histology","pmids":["31009037"],"confidence":"High","gaps":["Mechanism connecting AHR loss to foveal hypoplasia not defined","Whether myelination defect explains the nystagmus fully unresolved"]},{"year":2019,"claim":"Connected AHR loss to developmental endocrine phenotypes via Notch and ERα dysregulation in testis and mammary tissue.","evidence":"Ahr-/- mice with gene expression, histology, and serum hormone measurements","pmids":["27688768"],"confidence":"Medium","gaps":["Direct versus indirect regulation of Notch genes not distinguished","Relationship to the AHR-CUL4B/ERα degradation mechanism not integrated"]},{"year":2020,"claim":"Identified IL4I1 tryptophan catabolism as an endogenous source of AHR agonists driving tumor cell motility and immune suppression.","evidence":"Pan-tissue AHR signature, biochemical metabolite assays, and IL4I1-manipulated CLL mouse model","pmids":["32818467"],"confidence":"Medium","gaps":["Relative contribution of indoles versus kynurenic acid in vivo unclear","Direct AHR target genes mediating motility not mapped"]},{"year":2021,"claim":"Defined how AHR controls NK cell motility, transcriptionally inducing ASB2 to degrade filamin A and enable migration and tumor infiltration.","evidence":"Ahr-/- mice, AHR agonist treatment, ASB2 knockdown, and filamin A degradation/in vivo migration assays","pmids":["33717133"],"confidence":"Medium","gaps":["Direct AHR binding at the ASB2 locus not shown","Single lab without reciprocal genetic confirmation"]},{"year":2021,"claim":"Showed AHR is required for aflatoxin B1 hepatotoxicity, with AFB1 binding the AHR N-terminus to drive nuclear translocation and P450 induction generating DNA adducts.","evidence":"Genome-wide CRISPR screen, AHR-knockout cells, adduct quantification, and translocation assays","pmids":["34373448"],"confidence":"Medium","gaps":["Structural basis of N-terminal AFB1 binding not resolved","Whether this differs from canonical PAS-B ligand engagement unclear"]},{"year":2021,"claim":"Implicated AHR in coronavirus infection, with viral activation of AHR and AHR inhibition suppressing HCoV-229E and SARS-CoV-2 replication.","evidence":"In vitro viral replication assays with AHR inhibitors and patient lung scRNA-seq","pmids":["34446714"],"confidence":"Medium","gaps":["Mechanism by which AHR signaling supports viral replication not defined","Causality in patients inferred from expression only"]},{"year":2022,"claim":"Established a metabolic logic for AHR-driven keratinocyte differentiation: AHR represses glycolytic genes to raise SIRT1 in a pyruvate-dependent manner.","evidence":"ChIP, metabolic assays, protein measurements, and SIRT1 loss-of-function in keratinocytes","pmids":["30393078"],"confidence":"Medium","gaps":["Direct repression mechanism at SLC2A1/ENO1 versus indirect effects not fully separated","In vivo skin relevance not tested in this study"]},{"year":2022,"claim":"Linked UVB-induced DNA damage to AHR-driven skin aging, showing AHR cooperates with SP1 to induce MMP2/MMP11 and that AHR antagonists reduce wrinkling.","evidence":"HaCaT mechanistic studies with AHR/SP1 inhibition, reporter assays, and a mouse wrinkle model","pmids":["35316219"],"confidence":"Medium","gaps":["Direct AHR–SP1 promoter co-occupancy not structurally defined","Selectivity for MMP2/MMP11 over MMP1/3 mechanistically unexplained"]},{"year":2023,"claim":"Provided the structural basis of chaperone-held AHR, resolving the bridge motif inserting into Hsp90 and XAP2 stabilization of ligand-free PAS-B.","evidence":"Cryo-EM of Hsp90–AHR–p23 (±XAP2) with mutagenesis","pmids":["36649707"],"confidence":"High","gaps":["Conformational changes accompanying ligand binding and release not captured","Structure of the active AHR–ARNT–DNA complex not resolved here"]},{"year":2023,"claim":"Defined endothelial AHR as a sensor of dietary metabolites that maintains vascular quiescence and barrier integrity, protecting against influenza and enteric infection.","evidence":"Endothelial-specific AHR conditional knockouts, single-cell atlases, permeability assays, and infection challenge","pmids":["37587341","37586410"],"confidence":"High","gaps":["Specific dietary ligands sensed in each vascular bed not fully identified","Direct target genes downstream of apelin-APJ engagement not enumerated"]},{"year":2023,"claim":"Showed nutrient context tunes AHR sensitivity, with tryptophan deprivation inducing AHR and GCN2-dependent LAT1 to amplify kynurenine-driven AHR signaling and Treg differentiation.","evidence":"RT-qPCR, western blot, Ahr-variant and knockout T cells, and in vitro Treg differentiation","pmids":["37344101"],"confidence":"Medium","gaps":["Mechanism of tryptophan-depletion-induced AHR overexpression not defined","In vivo tumor relevance not directly tested here"]},{"year":2024,"claim":"Connected AHR to macrophage-mediated immune suppression, showing AHR induces ALKAL1 to promote MerTK phosphorylation and immunosuppressive polarization.","evidence":"scRNA-seq, AHR antagonist studies, adoptive transfer, and targeted nanoparticle delivery in vivo","pmids":["39365866"],"confidence":"Medium","gaps":["Direct AHR occupancy at ALKAL1 not shown","Generalizability across tumor types not established"]},{"year":null,"claim":"How AHR integrates its canonical XRE-transcription, CUL4B-E3-ligase, and ligand-independent (Rb1/PKA) modes into a unified tissue-specific decision, and which endogenous ligands govern each context, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of the active AHR-ARNT-DNA complex in the timeline","The endogenous ligand repertoire across tissues is incompletely defined","Determinants selecting transcriptional versus E3-ligase output are unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,5,11]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,5]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[3]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[3]},{"term_id":"GO:0140299","term_label":"molecular sensor activity","supporting_discovery_ids":[7,17]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,1,4]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,4]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,10,22,23]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[1,3]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[12,19,20]}],"complexes":["Hsp90–AHR–AIP/XAP2–p23 cytoplasmic chaperone complex","AHR–ARNT heterodimer","CUL4B^AHR E3 ubiquitin ligase"],"partners":["ARNT","HSP90","AIP","P23","CUL4B","ESR1","AR","RB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P35869","full_name":"Aryl hydrocarbon receptor","aliases":["Class E basic helix-loop-helix protein 76","bHLHe76"],"length_aa":848,"mass_kda":96.1,"function":"Ligand-activated transcription factor that enables cells to adapt to changing conditions by sensing compounds from the environment, diet, microbiome and cellular metabolism, and which plays important roles in development, immunity and cancer (PubMed:23275542, PubMed:30373764, PubMed:32818467, PubMed:7961644). Upon ligand binding, translocates into the nucleus, where it heterodimerizes with ARNT and induces transcription by binding to xenobiotic response elements (XRE) (PubMed:23275542, PubMed:30373764, PubMed:7961644). Regulates a variety of biological processes, including angiogenesis, hematopoiesis, drug and lipid metabolism, cell motility and immune modulation (PubMed:12213388). Xenobiotics can act as ligands: upon xenobiotic-binding, activates the expression of multiple phase I and II xenobiotic chemical metabolizing enzyme genes (such as the CYP1A1 gene) (PubMed:7961644, PubMed:33193710). Mediates biochemical and toxic effects of halogenated aromatic hydrocarbons (PubMed:34521881, PubMed:7961644). Next to xenobiotics, natural ligands derived from plants, microbiota, and endogenous metabolism are potent AHR agonists (PubMed:18076143). Tryptophan (Trp) derivatives constitute an important class of endogenous AHR ligands (PubMed:32818467, PubMed:32866000). Acts as a negative regulator of anti-tumor immunity: indoles and kynurenic acid generated by Trp catabolism act as ligand and activate AHR, thereby promoting AHR-driven cancer cell motility and suppressing adaptive immunity (PubMed:32818467). Regulates the circadian clock by inhibiting the basal and circadian expression of the core circadian component PER1 (PubMed:28602820). Inhibits PER1 by repressing the CLOCK-BMAL1 heterodimer mediated transcriptional activation of PER1 (PubMed:28602820). The heterodimer ARNT:AHR binds to core DNA sequence 5'-TGCGTG-3' within the dioxin response element (DRE) of target gene promoters and activates their transcription (PubMed:28602820)","subcellular_location":"Cytoplasm; Nucleus","url":"https://www.uniprot.org/uniprotkb/P35869/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/AHR","classification":"Not Classified","n_dependent_lines":64,"n_total_lines":1208,"dependency_fraction":0.052980132450331126},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/AHR","total_profiled":1310},"omim":[{"mim_id":"620958","title":"FOVEAL HYPOPLASIA 3; FVH3","url":"https://www.omim.org/entry/620958"},{"mim_id":"618345","title":"RETINITIS PIGMENTOSA 85; RP85","url":"https://www.omim.org/entry/618345"},{"mim_id":"616888","title":"TRANSMEMBRANE PROTEIN 8B; TMEM8B","url":"https://www.omim.org/entry/616888"},{"mim_id":"612476","title":"BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR, ATF-LIKE; BATF","url":"https://www.omim.org/entry/612476"},{"mim_id":"611595","title":"THIOREDOXIN-LIKE 4A; TXNL4A","url":"https://www.omim.org/entry/611595"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/AHR"},"hgnc":{"alias_symbol":["bHLHe76"],"prev_symbol":[]},"alphafold":{"accession":"P35869","domains":[{"cath_id":"3.30.450.20","chopping":"39-87_113-180_200-274","consensus_level":"high","plddt":87.0316,"start":39,"end":274},{"cath_id":"3.30.450.20","chopping":"278-399","consensus_level":"high","plddt":86.7117,"start":278,"end":399}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P35869","model_url":"https://alphafold.ebi.ac.uk/files/AF-P35869-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P35869-F1-predicted_aligned_error_v6.png","plddt_mean":56.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=AHR","jax_strain_url":"https://www.jax.org/strain/search?query=AHR"},"sequence":{"accession":"P35869","fasta_url":"https://rest.uniprot.org/uniprotkb/P35869.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P35869/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P35869"}},"corpus_meta":[{"pmid":"12573486","id":"PMC_12573486","title":"Functional role of AhR in the expression of toxic effects by TCDD.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12573486","citation_count":580,"is_preprint":false},{"pmid":"28146477","id":"PMC_28146477","title":"Feedback control of AHR signalling regulates intestinal immunity.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28146477","citation_count":451,"is_preprint":false},{"pmid":"32818467","id":"PMC_32818467","title":"IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression.","date":"2020","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/32818467","citation_count":449,"is_preprint":false},{"pmid":"30003042","id":"PMC_30003042","title":"AhR signaling pathways and regulatory functions.","date":"2018","source":"Biochimie open","url":"https://pubmed.ncbi.nlm.nih.gov/30003042","citation_count":444,"is_preprint":false},{"pmid":"33742166","id":"PMC_33742166","title":"AHR in the intestinal microenvironment: safeguarding barrier function.","date":"2021","source":"Nature reviews. Gastroenterology & hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/33742166","citation_count":319,"is_preprint":false},{"pmid":"30924357","id":"PMC_30924357","title":"Tryptophan (Trp) modulates gut homeostasis via aryl hydrocarbon receptor (AhR).","date":"2019","source":"Critical reviews in food science and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/30924357","citation_count":248,"is_preprint":false},{"pmid":"30513921","id":"PMC_30513921","title":"The Role of the Aryl Hydrocarbon Receptor (AHR) in Immune and Inflammatory Diseases.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30513921","citation_count":242,"is_preprint":false},{"pmid":"32279195","id":"PMC_32279195","title":"The Aryl Hydrocarbon Receptor (AHR) as a Potential Target for the Control of Intestinal Inflammation: Insights from an Immune and Bacteria Sensor Receptor.","date":"2020","source":"Clinical reviews in allergy & immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32279195","citation_count":211,"is_preprint":false},{"pmid":"20106901","id":"PMC_20106901","title":"The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth.","date":"2010","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20106901","citation_count":188,"is_preprint":false},{"pmid":"11469723","id":"PMC_11469723","title":"Induction of CYP1A1. The AhR/DRE paradigm: transcription, receptor regulation, and expanding biological roles.","date":"2001","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/11469723","citation_count":182,"is_preprint":false},{"pmid":"19100241","id":"PMC_19100241","title":"AHR-mediated immunomodulation: the role of altered gene transcription.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19100241","citation_count":149,"is_preprint":false},{"pmid":"36528068","id":"PMC_36528068","title":"Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR/ARNT signaling pathway.","date":"2022","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36528068","citation_count":141,"is_preprint":false},{"pmid":"24239782","id":"PMC_24239782","title":"AhR signalling and dioxin toxicity.","date":"2013","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24239782","citation_count":140,"is_preprint":false},{"pmid":"18848820","id":"PMC_18848820","title":"Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18848820","citation_count":137,"is_preprint":false},{"pmid":"24966027","id":"PMC_24966027","title":"Role of AhR/ARNT system in skin homeostasis.","date":"2014","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/24966027","citation_count":130,"is_preprint":false},{"pmid":"18838062","id":"PMC_18838062","title":"AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18838062","citation_count":130,"is_preprint":false},{"pmid":"18848529","id":"PMC_18848529","title":"Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18848529","citation_count":127,"is_preprint":false},{"pmid":"10961990","id":"PMC_10961990","title":"Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein. The role of hsp90.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10961990","citation_count":127,"is_preprint":false},{"pmid":"19778576","id":"PMC_19778576","title":"AhR and ARNT modulate ER signaling.","date":"2009","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/19778576","citation_count":121,"is_preprint":false},{"pmid":"26700314","id":"PMC_26700314","title":"AHR Function in Lymphocytes: Emerging Concepts.","date":"2015","source":"Trends in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26700314","citation_count":120,"is_preprint":false},{"pmid":"11090948","id":"PMC_11090948","title":"Is CYP1A1 induction always related to AHR signaling pathway?","date":"2000","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/11090948","citation_count":118,"is_preprint":false},{"pmid":"35316219","id":"PMC_35316219","title":"UVB-mediated DNA damage induces matrix metalloproteinases to promote photoaging in an AhR- and SP1-dependent manner.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/35316219","citation_count":111,"is_preprint":false},{"pmid":"32932962","id":"PMC_32932962","title":"Aryl Hydrocarbon Receptor (AHR) Ligands as Selective AHR Modulators (SAhRMs).","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32932962","citation_count":111,"is_preprint":false},{"pmid":"36757399","id":"PMC_36757399","title":"Activation of aryl hydrocarbon receptor (AhR) in Alzheimer's disease: role of tryptophan metabolites generated by gut host-microbiota.","date":"2023","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/36757399","citation_count":103,"is_preprint":false},{"pmid":"28318896","id":"PMC_28318896","title":"Role of AHR and HIF-1α in Glioblastoma Metabolism.","date":"2017","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/28318896","citation_count":100,"is_preprint":false},{"pmid":"23220635","id":"PMC_23220635","title":"The AhR twist: ligand-dependent AhR signaling and pharmaco-toxicological implications.","date":"2012","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/23220635","citation_count":100,"is_preprint":false},{"pmid":"19027718","id":"PMC_19027718","title":"Timing is everything: consequences of transient and sustained AhR activity.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19027718","citation_count":98,"is_preprint":false},{"pmid":"34373448","id":"PMC_34373448","title":"AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma.","date":"2021","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/34373448","citation_count":96,"is_preprint":false},{"pmid":"21342125","id":"PMC_21342125","title":"The function of cytochrome P450 1A1 enzyme (CYP1A1) and aryl hydrocarbon receptor (AhR) in the placenta.","date":"2011","source":"Current pharmaceutical biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/21342125","citation_count":96,"is_preprint":false},{"pmid":"37587341","id":"PMC_37587341","title":"Endothelial AHR activity prevents lung barrier disruption in viral infection.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37587341","citation_count":95,"is_preprint":false},{"pmid":"34831399","id":"PMC_34831399","title":"Role of AHR Ligands in Skin Homeostasis and Cutaneous Inflammation.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34831399","citation_count":94,"is_preprint":false},{"pmid":"25286307","id":"PMC_25286307","title":"Intersection of AHR and Wnt signaling in development, health, and disease.","date":"2014","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25286307","citation_count":93,"is_preprint":false},{"pmid":"37344101","id":"PMC_37344101","title":"Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37344101","citation_count":91,"is_preprint":false},{"pmid":"31228464","id":"PMC_31228464","title":"Aryl hydrocarbon receptor (AHR): From selected human target genes and crosstalk with transcription factors to multiple AHR functions.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31228464","citation_count":84,"is_preprint":false},{"pmid":"18940186","id":"PMC_18940186","title":"The aryl hydrocarbon receptor (AhR) pathway as a regulatory pathway for cell adhesion and matrix metabolism.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18940186","citation_count":82,"is_preprint":false},{"pmid":"33396563","id":"PMC_33396563","title":"How the AHR Became Important in Cancer: The Role of Chronically Active AHR in Cancer Aggression.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33396563","citation_count":81,"is_preprint":false},{"pmid":"25256754","id":"PMC_25256754","title":"Microbiota control of a tryptophan-AhR pathway in disease tolerance to fungi.","date":"2014","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25256754","citation_count":76,"is_preprint":false},{"pmid":"23963493","id":"PMC_23963493","title":"Role of the aryl hydrocarbon receptor (AhR) in lung inflammation.","date":"2013","source":"Seminars in immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/23963493","citation_count":75,"is_preprint":false},{"pmid":"11382553","id":"PMC_11382553","title":"Interactions between aryl hydrocarbon receptor (AhR) and hypoxia signaling pathways.","date":"2001","source":"Environmental toxicology and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/11382553","citation_count":73,"is_preprint":false},{"pmid":"37963637","id":"PMC_37963637","title":"Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.","date":"2023","source":"Journal for immunotherapy of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37963637","citation_count":72,"is_preprint":false},{"pmid":"34446714","id":"PMC_34446714","title":"AHR signaling is induced by infection with coronaviruses.","date":"2021","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/34446714","citation_count":71,"is_preprint":false},{"pmid":"37586410","id":"PMC_37586410","title":"Endothelial sensing of AHR ligands regulates intestinal homeostasis.","date":"2023","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/37586410","citation_count":70,"is_preprint":false},{"pmid":"30055148","id":"PMC_30055148","title":"From TCDD-mediated toxicity to searches of physiologic AHR functions.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30055148","citation_count":70,"is_preprint":false},{"pmid":"33451095","id":"PMC_33451095","title":"AhR and Cancer: From Gene Profiling to Targeted Therapy.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33451095","citation_count":67,"is_preprint":false},{"pmid":"38882491","id":"PMC_38882491","title":"The gut microbiota-aromatic hydrocarbon receptor (AhR) axis mediates the anticolitic effect of polyphenol-rich extracts from Sanghuangporus.","date":"2024","source":"iMeta","url":"https://pubmed.ncbi.nlm.nih.gov/38882491","citation_count":65,"is_preprint":false},{"pmid":"32535108","id":"PMC_32535108","title":"Aryl hydrocarbon receptor (AHR) functions: Balancing opposing processes including inflammatory reactions.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32535108","citation_count":63,"is_preprint":false},{"pmid":"25368620","id":"PMC_25368620","title":"Immunological Relevance of the Coevolution of IDO1 and AHR.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25368620","citation_count":63,"is_preprint":false},{"pmid":"18983832","id":"PMC_18983832","title":"AhR protein trafficking and function in the skin.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18983832","citation_count":62,"is_preprint":false},{"pmid":"22628113","id":"PMC_22628113","title":"The evolving role of the aryl hydrocarbon receptor (AHR) in the normophysiology of hematopoiesis.","date":"2012","source":"Stem cell reviews and reports","url":"https://pubmed.ncbi.nlm.nih.gov/22628113","citation_count":58,"is_preprint":false},{"pmid":"32597823","id":"PMC_32597823","title":"AhR and IDO1 in pathogenesis of Covid-19 and the \"Systemic AhR Activation Syndrome:\" a translational review and therapeutic perspectives.","date":"2020","source":"Restorative neurology and neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32597823","citation_count":58,"is_preprint":false},{"pmid":"32784381","id":"PMC_32784381","title":"How the AHR Became Important in Intestinal Homeostasis-A Diurnal FICZ/AHR/CYP1A1 Feedback Controls Both Immunity and Immunopathology.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32784381","citation_count":58,"is_preprint":false},{"pmid":"31721255","id":"PMC_31721255","title":"The aryl hydrocarbon receptor (AhR) as a breast cancer drug target.","date":"2019","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/31721255","citation_count":57,"is_preprint":false},{"pmid":"28851966","id":"PMC_28851966","title":"AhR-deficiency as a cause of demyelinating disease and inflammation.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28851966","citation_count":57,"is_preprint":false},{"pmid":"31453421","id":"PMC_31453421","title":"Aryl Hydrocarbon Receptor (AhR) Ligands as Selective AhR Modulators: Genomic Studies.","date":"2018","source":"Current opinion in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/31453421","citation_count":57,"is_preprint":false},{"pmid":"36198709","id":"PMC_36198709","title":"AHR is a master regulator of diverse pathways in endogenous metabolism.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36198709","citation_count":54,"is_preprint":false},{"pmid":"29643980","id":"PMC_29643980","title":"Perillaldehyde Inhibits AHR Signaling and Activates NRF2 Antioxidant Pathway in Human Keratinocytes.","date":"2018","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/29643980","citation_count":52,"is_preprint":false},{"pmid":"22254019","id":"PMC_22254019","title":"Potential health-modulating effects of isoflavones and metabolites via activation of PPAR and AhR.","date":"2010","source":"Nutrients","url":"https://pubmed.ncbi.nlm.nih.gov/22254019","citation_count":51,"is_preprint":false},{"pmid":"33451129","id":"PMC_33451129","title":"The Landscape of AhR Regulators and Coregulators to Fine-Tune AhR Functions.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33451129","citation_count":50,"is_preprint":false},{"pmid":"18983986","id":"PMC_18983986","title":"Crosstalk between the AHR signaling pathway and circadian rhythm.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18983986","citation_count":49,"is_preprint":false},{"pmid":"17368311","id":"PMC_17368311","title":"The intersection between the aryl hydrocarbon receptor (AhR)- and retinoic acid-signaling pathways.","date":"2007","source":"Vitamins and hormones","url":"https://pubmed.ncbi.nlm.nih.gov/17368311","citation_count":47,"is_preprint":false},{"pmid":"38067179","id":"PMC_38067179","title":"AhR, PXR and CAR: From Xenobiotic Receptors to Metabolic Sensors.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/38067179","citation_count":45,"is_preprint":false},{"pmid":"18938144","id":"PMC_18938144","title":"AHR-dependent misregulation of Wnt signaling disrupts tissue regeneration.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18938144","citation_count":45,"is_preprint":false},{"pmid":"35204110","id":"PMC_35204110","title":"AHR and NRF2 in Skin Homeostasis and Atopic Dermatitis.","date":"2022","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/35204110","citation_count":43,"is_preprint":false},{"pmid":"19640236","id":"PMC_19640236","title":"Relevance of the aryl hydrocarbon receptor (AhR) for clinical toxicology.","date":"2009","source":"Clinical toxicology (Philadelphia, Pa.)","url":"https://pubmed.ncbi.nlm.nih.gov/19640236","citation_count":43,"is_preprint":false},{"pmid":"36428667","id":"PMC_36428667","title":"The Role of the Aryl Hydrocarbon Receptor (AhR) and Its Ligands in Breast Cancer.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36428667","citation_count":41,"is_preprint":false},{"pmid":"36649707","id":"PMC_36649707","title":"Cryo-EM structure of the cytosolic AhR complex.","date":"2023","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/36649707","citation_count":41,"is_preprint":false},{"pmid":"30508524","id":"PMC_30508524","title":"Human AHR functions in vascular tissue: Pro- and anti-inflammatory responses of AHR agonists in atherosclerosis.","date":"2018","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30508524","citation_count":41,"is_preprint":false},{"pmid":"37104918","id":"PMC_37104918","title":"Spermidine protects intestinal mucosal barrier function in mice colitis via the AhR/Nrf2 and AhR/STAT3 signaling pathways.","date":"2023","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37104918","citation_count":39,"is_preprint":false},{"pmid":"25360135","id":"PMC_25360135","title":"AhR-Mediated, Non-Genomic Modulation of IDO1 Function.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25360135","citation_count":39,"is_preprint":false},{"pmid":"27688768","id":"PMC_27688768","title":"Dysregulation of Notch and ERα signaling in AhR-/- male mice.","date":"2016","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/27688768","citation_count":39,"is_preprint":false},{"pmid":"18950284","id":"PMC_18950284","title":"An update on the dietary ligands of the AhR.","date":"2008","source":"Expert opinion on drug metabolism & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/18950284","citation_count":37,"is_preprint":false},{"pmid":"35163440","id":"PMC_35163440","title":"The Aryl Hydrocarbon Receptor (AHR): A Novel Therapeutic Target for Pulmonary Diseases?","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35163440","citation_count":36,"is_preprint":false},{"pmid":"35987825","id":"PMC_35987825","title":"Aryl hydrocarbon receptor (AhR) reveals evidence of antagonistic pleiotropy in the regulation of the aging process.","date":"2022","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/35987825","citation_count":36,"is_preprint":false},{"pmid":"33066667","id":"PMC_33066667","title":"The Role of Aryl-Hydrocarbon Receptor (AhR) in Osteoclast Differentiation and Function.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/33066667","citation_count":34,"is_preprint":false},{"pmid":"37106727","id":"PMC_37106727","title":"Tumor-Suppressive Functions of the Aryl Hydrocarbon Receptor (AhR) and AhR as a Therapeutic Target in Cancer.","date":"2023","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/37106727","citation_count":33,"is_preprint":false},{"pmid":"19013136","id":"PMC_19013136","title":"Role of cAMP in mediating AHR signaling.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19013136","citation_count":33,"is_preprint":false},{"pmid":"27805907","id":"PMC_27805907","title":"Human and rodent aryl hydrocarbon receptor (AHR): from mediator of dioxin toxicity to physiologic AHR functions and therapeutic options.","date":"2017","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/27805907","citation_count":33,"is_preprint":false},{"pmid":"16137816","id":"PMC_16137816","title":"PPARalpha activation potentiates AhR-induced CYP1A1 expression.","date":"2005","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/16137816","citation_count":33,"is_preprint":false},{"pmid":"18977204","id":"PMC_18977204","title":"AHR signaling in prostate growth, morphogenesis, and disease.","date":"2008","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18977204","citation_count":33,"is_preprint":false},{"pmid":"30314280","id":"PMC_30314280","title":"Isopsoralen Enhanced Osteogenesis by Targeting AhR/ERα.","date":"2018","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30314280","citation_count":32,"is_preprint":false},{"pmid":"31681212","id":"PMC_31681212","title":"Involvement of Ahr Pathway in Toxicity of Aflatoxins and Other Mycotoxins.","date":"2019","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/31681212","citation_count":31,"is_preprint":false},{"pmid":"30393078","id":"PMC_30393078","title":"AHR Regulates Metabolic Reprogramming to Promote SIRT1-Dependent Keratinocyte Differentiation.","date":"2018","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/30393078","citation_count":31,"is_preprint":false},{"pmid":"38518634","id":"PMC_38518634","title":"Wogonin improves colitis by activating the AhR pathway to regulate the plasticity of ILC3/ILC1.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38518634","citation_count":30,"is_preprint":false},{"pmid":"32738369","id":"PMC_32738369","title":"Assessing the receptor-mediated activity of PAHs using AhR-, ERα- and PPARγ- CALUX bioassays.","date":"2020","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/32738369","citation_count":30,"is_preprint":false},{"pmid":"31009037","id":"PMC_31009037","title":"Homozygous stop mutation in AHR causes autosomal recessive foveal hypoplasia and infantile nystagmus.","date":"2019","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/31009037","citation_count":30,"is_preprint":false},{"pmid":"24469321","id":"PMC_24469321","title":"Aryl hydrocarbon receptor (AhR) agonists increase airway epithelial matrix metalloproteinase activity.","date":"2014","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/24469321","citation_count":28,"is_preprint":false},{"pmid":"33717133","id":"PMC_33717133","title":"AHR Regulates NK Cell Migration via ASB2-Mediated Ubiquitination of Filamin A.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33717133","citation_count":27,"is_preprint":false},{"pmid":"38604309","id":"PMC_38604309","title":"6PPDQ induces cardiomyocyte senescence via AhR/ROS-mediated autophagic flux blockage.","date":"2024","source":"Environmental pollution (Barking, Essex : 1987)","url":"https://pubmed.ncbi.nlm.nih.gov/38604309","citation_count":27,"is_preprint":false},{"pmid":"28985473","id":"PMC_28985473","title":"Red Clover Aryl Hydrocarbon Receptor (AhR) and Estrogen Receptor (ER) Agonists Enhance Genotoxic Estrogen Metabolism.","date":"2017","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/28985473","citation_count":27,"is_preprint":false},{"pmid":"33227291","id":"PMC_33227291","title":"Aryl hydrocarbon receptor (AHR), integrating energy metabolism and microbial or obesity-mediated inflammation.","date":"2020","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33227291","citation_count":26,"is_preprint":false},{"pmid":"37480978","id":"PMC_37480978","title":"Deciphering the roles of aryl hydrocarbon receptor (AHR) in regulating carcinogenesis.","date":"2023","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37480978","citation_count":26,"is_preprint":false},{"pmid":"37031728","id":"PMC_37031728","title":"Aryl hydrocarbon receptor (AhR) impairs circadian regulation: Impact on the aging process.","date":"2023","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/37031728","citation_count":25,"is_preprint":false},{"pmid":"28649092","id":"PMC_28649092","title":"Aryl hydrocarbon receptor (AHR) is a potential tumour suppressor in pituitary adenomas.","date":"2017","source":"Endocrine-related cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28649092","citation_count":25,"is_preprint":false},{"pmid":"39415055","id":"PMC_39415055","title":"The role of the AHR in host-pathogen interactions.","date":"2024","source":"Nature reviews. Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39415055","citation_count":24,"is_preprint":false},{"pmid":"36139083","id":"PMC_36139083","title":"Gut Microbiota Regulation of AHR Signaling in Liver Disease.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/36139083","citation_count":24,"is_preprint":false},{"pmid":"30011787","id":"PMC_30011787","title":"Therapeutic Agents with AHR Inhibiting and NRF2 Activating Activity for Managing Chloracne.","date":"2018","source":"Antioxidants (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/30011787","citation_count":24,"is_preprint":false},{"pmid":"29302888","id":"PMC_29302888","title":"Overexpression of aryl hydrocarbon receptor (AHR) signalling pathway in human meningioma.","date":"2018","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29302888","citation_count":24,"is_preprint":false},{"pmid":"30333853","id":"PMC_30333853","title":"Investigation of Nrf2, AhR and ATF4 Activation in Toxicogenomic Databases.","date":"2018","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30333853","citation_count":24,"is_preprint":false},{"pmid":"39365866","id":"PMC_39365866","title":"MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/39365866","citation_count":23,"is_preprint":false},{"pmid":"39242971","id":"PMC_39242971","title":"The influence of AHR on immune and tissue biology.","date":"2024","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39242971","citation_count":23,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44474,"output_tokens":5670,"usd":0.109236,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14288,"output_tokens":6819,"usd":0.120957,"stage2_stop_reason":"end_turn"},"total_usd":0.230193,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"Ligand-bound AHR translocates from cytoplasm to nucleus, dissociates from Hsp90, and heterodimerizes with ARNT; the AHR/ARNT heterodimer binds XRE (xenobiotic response elements) in the promoter of target genes such as CYP1A1 to drive their transcription.\",\n      \"method\": \"Mechanistic studies of CYP1A1 induction; ligand binding, nuclear translocation, and DNA-binding assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — canonical mechanism established by multiple labs across decades; replicated in numerous independent studies\",\n      \"pmids\": [\"12573486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In the cytoplasm, AHR interacts with Hsp90 and the immunophilin chaperone AIP (AhR-interacting protein) for proper folding and ligand-binding competence; after nuclear entry, agonist-activated AHR is degraded via the ubiquitin–26S proteasome pathway, limiting the duration of transcriptional activation.\",\n      \"method\": \"Biochemical characterization, proteasome inhibition experiments, receptor turnover assays\",\n      \"journal\": \"Current drug metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods, independently replicated across labs\",\n      \"pmids\": [\"11469723\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"AIP binds to AHR in an Hsp90-dependent manner: AIP binds the C-terminus of Hsp90 via its tetratricopeptide repeat domain (mutation K266A abolishes Hsp90 binding and reduces AHR binding by 75–80%), while the alpha-helical C-terminus of AIP is absolutely required for AHR interaction but not for Hsp90 binding. Hsp90 is required for AHR–AIP complex formation.\",\n      \"method\": \"Reticulocyte lysate binding assays, site-directed mutagenesis, geldanamycin/ATP sensitivity tests, deletion analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution in reticulocyte lysate with mutagenesis, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"10961990\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Ligand-activated AHR assembles a CUL4B-based E3 ubiquitin ligase complex (CUL4B^AHR), in which AHR acts as a substrate-recognition subunit to recruit estrogen receptor α (ERα) and androgen receptor (AR) for ubiquitin-mediated proteolysis, defining a non-transcriptional role for AHR as a ligand-dependent E3 ubiquitin ligase.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, proteasome-dependent degradation assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — co-IP and functional ubiquitination assays; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"18838062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AHR possesses a functional nuclear localization signal (NLS) and a nuclear export signal (NES); phosphorylation of residues near these signals controls AHR's distribution between cytoplasm and nucleus. Cell density modulates both AHR intracellular localization and its transactivation of target genes including the transcriptional repressor Slug.\",\n      \"method\": \"Subcellular fractionation, live-cell imaging, phosphorylation studies, NLS/NES mutagenesis\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct localization experiments with functional consequence, single lab\",\n      \"pmids\": [\"18983832\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"AHR and HIF-1α signaling pathways mutually repress each other by competing for the shared partner ARNT: TCDD-activated AHR reduced hypoxia-inducible reporter activity, and hypoxia-mimicking agents reduced AHR-mediated CYP1A1 activity and DRE-binding; the interaction is attributable to changes in DNA-binding activity at DRE and HIF-1 binding sites.\",\n      \"method\": \"Reporter gene assays, EMSA (DNA-binding assays), enzyme activity assays in multiple cell lines\",\n      \"journal\": \"Environmental toxicology and pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple cell lines and orthogonal readouts; single study\",\n      \"pmids\": [\"11382553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"AHR agonists increase MMP-1 expression in bronchial epithelial cells via a non-canonical AHR pathway: AHR agonists elevate cytosolic calcium, activating CaMKII, which activates MAPK pathways, phosphorylating c-Jun, c-Fos, and ATF-2, which bind AP-1 elements in the MMP-1 promoter; upregulated MMP-1 further activates MMP-2 and MMP-9.\",\n      \"method\": \"Reporter assays, pharmacological inhibitors, kinase activity assays, ChIP-like promoter analysis\",\n      \"journal\": \"Journal of molecular medicine (Berlin, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pathway inhibitors and orthogonal readouts, single lab\",\n      \"pmids\": [\"24469321\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Constitutive expression of Cyp1a1 in mice depletes endogenous AHR ligands, generating a quasi-AHR-deficient state with loss of AHR-dependent ILC3 and Th17 cells and increased susceptibility to enteric infection, demonstrating that CYP1A1 enzymes act as a feedback mechanism regulating AHR ligand availability in vivo.\",\n      \"method\": \"Transgenic mouse model (constitutive Cyp1a1 expression throughout body or restricted to intestinal epithelium), immune cell phenotyping, infection challenge\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic mouse model with specific phenotypic readout and dietary rescue, published in Nature\",\n      \"pmids\": [\"28146477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"IL4I1 (interleukin-4-induced-1) activates AHR through generation of indole metabolites and kynurenic acid from tryptophan catabolism, promoting cancer cell motility and suppression of adaptive immunity.\",\n      \"method\": \"Pan-tissue AHR signature analysis, biochemical assays of IL4I1 metabolite production, mouse model of CLL with IL4I1 manipulation\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical pathway and in vivo mouse model, single study\",\n      \"pmids\": [\"32818467\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Cryo-EM structures of the Hsp90–AHR–p23 complex (with or without XAP2) resolved the mouse AHR PAS-B domain; a highly conserved 'bridge motif' of AHR is responsible for interaction with the Hsp90 dimeric lumen; ligand-free AHR PAS-B is stabilized by XAP2 binding; conserved DE-loop residues and pocket inner residues are important for ligand binding.\",\n      \"method\": \"Cryo-EM structure determination, mutagenesis, protein purification\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — cryo-EM structure with mutagenesis validation, single study\",\n      \"pmids\": [\"36649707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AHR regulates NK cell migration via transcriptional induction of ASB2, which promotes ubiquitin-mediated degradation of filamin A; loss of AHR reduces ASB2 expression, stabilizes filamin A, and impairs NK cell migration and tumor infiltration in vivo.\",\n      \"method\": \"Ahr-/- mouse model, gene expression analysis, AHR agonist treatment, ASB2 knockdown, filamin A degradation assays, in vivo tumor migration assay\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO and knockdown with mechanistic pathway placement, single lab\",\n      \"pmids\": [\"33717133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"AHR activation in keratinocytes promotes SIRT1-dependent differentiation by repressing glycolysis: AHR binds and reduces expression of the glucose transporter SLC2A1 and glycolytic enzyme ENO1, lowering glucose uptake and ATP; this metabolic shift increases SIRT1 protein levels in a pyruvate-dependent manner, and SIRT1 is required for AHR-induced keratinocyte differentiation.\",\n      \"method\": \"ChIP, qPCR, metabolic assays (glucose uptake, pyruvate/lactate), protein level measurements, pharmacological inhibitors, SIRT1 loss-of-function\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and multiple orthogonal metabolic and functional assays, single lab\",\n      \"pmids\": [\"30393078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"AHR loss-of-function in Ahr-/- mice causes dysregulation of Notch and ERα signaling: reduced expression of Notch1, Notch3, and their target HES1 leads to early spermatocyte maturation and depletion of spermatids (reduced fertility); meanwhile, absence of AHR in the mammary fat pad leads to overexpression of ERα and enhanced ductal growth.\",\n      \"method\": \"Ahr-/- mouse model, gene expression analysis, histology, serum hormone measurements\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with specific phenotypic readouts, single lab\",\n      \"pmids\": [\"27688768\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AHR exerts a cell-cycle regulatory, tumor-suppressive function in pituitary cells independent of exogenous ligand: AHR overexpression in GH3 cells reduced E2F-driven transcription, altered cell cycle regulator gene expression, and increased G0/G1 fraction; co-immunoprecipitation confirmed AHR–retinoblastoma protein (Rb1) interaction as the functional mechanism.\",\n      \"method\": \"AHR overexpression, siRNA knockdown, co-immunoprecipitation (AHR–Rb1), cell cycle analysis, qPCR\",\n      \"journal\": \"Endocrine-related cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP with functional cell cycle readouts, gain- and loss-of-function, single lab\",\n      \"pmids\": [\"28649092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AHR is activated by coronavirus infection (including SARS-CoV-2); pharmacological inhibition of AHR suppressed HCoV-229E and SARS-CoV-2 replication in vitro, and single-cell RNA-seq from COVID-19 patients detected increased AHR and AHR target gene expression in infected lung epithelial cells.\",\n      \"method\": \"In vitro viral replication assay with AHR inhibitors, single-cell RNA-seq analysis of patient lung tissue\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro functional assay and patient scRNA-seq, single lab\",\n      \"pmids\": [\"34446714\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AHR is required for AFB1 (aflatoxin B1) toxicity in hepatocytes: AHR-deficient cells tolerated high AFB1 concentrations with significantly decreased AFB1-DNA adduct formation; AFB1 directly binds the N-terminus of AHR triggering nuclear translocation; AHR mediates P450 enzyme expression induced by AFB1.\",\n      \"method\": \"Genome-wide CRISPR-Cas9 screen, AHR-knockout cell lines, AFB1-DNA adduct quantification, nuclear translocation assay\",\n      \"journal\": \"Signal transduction and targeted therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR screen and mechanistic follow-up in AHR-KO cells, single study\",\n      \"pmids\": [\"34373448\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In lung endothelial cells, AHR is highly active and protects against influenza-induced vascular leakage by engaging tissue-protective transcriptional networks including the vasoactive apelin-APJ peptide system; endothelial-specific AHR deletion exacerbates lung damage and promotes apoptosis of airway epithelial cells.\",\n      \"method\": \"Endothelial-specific AHR conditional knockout mouse model, lung permeability assays, influenza infection, transcriptomic analysis\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type specific genetic KO with defined mechanistic pathway in Nature\",\n      \"pmids\": [\"37587341\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"AHR acts as a critical node for endothelial sensing of dietary metabolites in the intestine; AHR-mediated signaling in endothelial cells promotes cellular quiescence, vascular normalcy, and restrains inflammatory responses; endothelial AHR deficiency results in dysregulated inflammatory responses and initiation of proliferative pathways; endothelial AHR sensing of dietary ligands is required for protection against enteric infection.\",\n      \"method\": \"Single-cell endothelial atlas, endothelial-specific AHR conditional knockout, transcriptomic analysis, infection challenge\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-type specific genetic KO with scRNA-seq and functional infection readout, published in Nature\",\n      \"pmids\": [\"37586410\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"UVB-generated DNA damage activates AHR, which cooperates with SP1 to induce MMP2 and MMP11 expression (but not MMP1/3) in keratinocytes; topical AHR antagonists (vitamin B12 and folic acid) ameliorate UVB-induced wrinkle formation in mice while reducing MMP2 expression.\",\n      \"method\": \"Mechanistic studies in HaCaT keratinocytes with AHR/SP1 pathway inhibition/knockdown, reporter assays, mouse wrinkle model with topical antagonists\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic cell studies with in vivo validation, single lab\",\n      \"pmids\": [\"35316219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Homozygous stop-gain mutation (p.Q621*) in AHR causes autosomal recessive foveal hypoplasia and infantile nystagmus in humans; AHR loss-of-function in Ahr-/- mice impairs optic nerve myelin sheath formation and produces conjugate horizontal pendular nystagmus, identifying AHR as a physiological regulator of myelination.\",\n      \"method\": \"Whole exome sequencing (human), Ahr-/- mouse model, optic nerve histology\",\n      \"journal\": \"Brain : a journal of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetic finding corroborated by mouse KO phenotype with histological mechanistic readout\",\n      \"pmids\": [\"31009037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"AHR deficiency in mice leads to demyelinating disease: Ahr-/- optic nerves show altered lipid composition of the myelin sheath and decreased expression of myelin-associated glycoprotein (MAG), accompanied by increased pro-inflammatory cytokines; inflammation is causally linked to AHR-dependent decreased MAG expression.\",\n      \"method\": \"Ahr-/- mouse model, lipid analysis, immunostaining for MAG, cytokine expression profiling\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with specific molecular and histological readouts, single lab\",\n      \"pmids\": [\"28851966\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"cAMP-dependent protein kinase (PKA) can render AHR nuclear and activate AHR-sensitive genes through a mechanism fundamentally different from exogenous ligand-driven nuclear entry, indicating a ligand-independent mode of AHR activation.\",\n      \"method\": \"PKA activation/inhibition studies, nuclear import assays\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, mechanistic follow-up limited; abstract does not fully describe experimental methods\",\n      \"pmids\": [\"19013136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Tryptophan deprivation sensitizes the AHR pathway by inducing AHR overexpression (independent of kynurenine but triggered by tryptophan depletion itself) and by increasing cellular kynurenine uptake via GCN2-dependent upregulation of the transporter LAT1 (SLC7A5), so that normally weak AHR agonists such as kynurenine potently activate AHR target genes and potentiate Treg differentiation.\",\n      \"method\": \"RT-qPCR, western blot, Ahr allele variant mouse T cells, Ahr knockout T cells, in vitro Treg differentiation assay\",\n      \"journal\": \"Journal for immunotherapy of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods and genetic models, single lab\",\n      \"pmids\": [\"37344101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In MerTK+ tumor-associated macrophages, AHR transcriptionally induces ALKAL1, which facilitates MerTK phosphorylation, resulting in heightened phagocytic activity and polarization toward an immunosuppressive phenotype; targeted delivery of an AHR antagonist to tumor-associated macrophages suppressed MerTK expression and improved anti-PD-L1 therapy efficacy.\",\n      \"method\": \"scRNA-seq, mechanistic studies with AHR antagonist, adoptive macrophage transfer, targeted nanoparticle delivery in vivo\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — mechanistic studies with in vivo validation, single lab\",\n      \"pmids\": [\"39365866\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"AHR is a cytoplasmic, ligand-activated transcription factor of the bHLH-PAS family that, upon ligand binding, dissociates from its Hsp90–AIP–p23 chaperone complex (structurally resolved by cryo-EM), translocates to the nucleus via a regulated NLS/NES phosphorylation mechanism, heterodimerizes with ARNT, and binds XRE sequences to drive transcription of target genes (CYP1A1, CYP1B1, etc.); activated nuclear AHR is subsequently degraded by the ubiquitin–26S proteasome pathway. Beyond canonical transcription, AHR assembles a CUL4B E3 ubiquitin ligase complex to promote proteolysis of ERα and AR, regulates NK cell migration through ASB2-mediated filamin A degradation, controls keratinocyte differentiation by repressing glycolysis and raising SIRT1, engages the apelin-APJ system to protect lung endothelial barrier integrity, and physiologically regulates optic nerve myelination—all functions revealed by genetic loss-of-function models and mechanistic biochemical studies.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"AHR is a ligand-activated bHLH-PAS transcription factor that links sensing of xenobiotic and endogenous small molecules to a broad transcriptional program governing detoxification, tissue homeostasis, and immunity [#0, #7]. In the unliganded state AHR resides in the cytoplasm within a chaperone complex with Hsp90 and the immunophilin AIP/XAP2; AIP docks onto the Hsp90 C-terminus through its tetratricopeptide-repeat domain and contacts AHR through its alpha-helical C-terminus, stabilizing the ligand-binding-competent PAS-B domain [#1, #2, #9]. Cryo-EM of the Hsp90\\u2013AHR\\u2013p23 complex resolved a conserved AHR 'bridge motif' that inserts into the Hsp90 dimeric lumen and showed that XAP2 stabilizes ligand-free PAS-B, with DE-loop and pocket residues forming the ligand-binding cavity [#9]. Upon ligand binding AHR translocates to the nucleus\\u2014a redistribution controlled by phosphorylation near its NLS/NES\\u2014dissociates from Hsp90, heterodimerizes with ARNT, and binds xenobiotic response elements to drive transcription of CYP1A1 and other targets, after which nuclear AHR is degraded by the ubiquitin\\u201326S proteasome to limit signaling duration [#0, #1, #4]. The CYP1A1 enzymes it induces in turn deplete endogenous ligands, forming a feedback loop that sets AHR activity in vivo [#7], and AHR activity is further tuned by competition with HIF-1\\u03b1 for shared ARNT and by ligand supply from tryptophan-catabolizing pathways such as IL4I1 [#5, #8]. Beyond canonical transcription, ligand-activated AHR serves as the substrate-recognition subunit of a CUL4B E3 ubiquitin ligase that targets ER\\u03b1 and AR for proteolysis [#3]. Across tissues AHR executes protective and differentiation programs: it sustains intestinal ILC3/Th17 immunity [#7], drives NK cell migration via ASB2-mediated filamin A degradation [#10], promotes SIRT1-dependent keratinocyte differentiation by repressing glycolytic genes SLC2A1 and ENO1 [#11], and in endothelium senses dietary metabolites to maintain vascular quiescence and barrier integrity, engaging the apelin-APJ system to protect against influenza- and infection-induced damage [#16, #17]. A homozygous stop-gain mutation (p.Q621*) in AHR causes autosomal recessive foveal hypoplasia and infantile nystagmus, and AHR-null mice show defective optic nerve myelination, establishing AHR as a physiological regulator of myelination [#19, #20].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established how AHR is held in a ligand-competent state, defining the architecture of the cytoplasmic chaperone complex through which AHR is folded and primed.\",\n      \"evidence\": \"Reticulocyte-lysate binding assays with AIP/Hsp90 mutagenesis and geldanamycin/ATP sensitivity tests\",\n      \"pmids\": [\"10961990\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and dynamics of the full complex in cells not resolved\", \"Did not show how ligand binding triggers complex dissociation\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved the lifecycle of AHR signaling \\u2014 cytoplasmic chaperoning for ligand competence followed by proteasomal degradation of activated nuclear receptor \\u2014 establishing that signal duration is actively limited.\",\n      \"evidence\": \"Biochemical characterization, proteasome inhibition, and receptor turnover assays\",\n      \"pmids\": [\"11469723\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"E3 ligase responsible for activated-AHR turnover not identified here\", \"Coupling between transcription and degradation not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed that AHR and HIF-1\\u03b1 are not independent pathways but compete for the shared dimerization partner ARNT, explaining crosstalk between xenobiotic and hypoxic signaling.\",\n      \"evidence\": \"Reporter assays, EMSA at DRE/HIF-1 sites, and enzyme activity assays across multiple cell lines\",\n      \"pmids\": [\"11382553\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether competition occurs at ARNT abundance or DNA-binding step not fully separated\", \"In vivo physiological relevance not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Consolidated the canonical mechanism: ligand-triggered nuclear translocation, Hsp90 dissociation, ARNT heterodimerization, and XRE-driven transcription of CYP1A1.\",\n      \"evidence\": \"Mechanistic CYP1A1 induction studies with ligand binding, translocation, and DNA-binding assays\",\n      \"pmids\": [\"12573486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full set of physiological target genes not enumerated\", \"Tissue-specific cofactor requirements not defined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Revealed a non-transcriptional function: ligand-activated AHR assembles a CUL4B E3 ligase and acts as a substrate-recognition subunit to degrade ER\\u03b1 and AR, uncoupling AHR action from DNA binding.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination, and proteasome-dependent degradation assays\",\n      \"pmids\": [\"18838062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of substrate selection by the AHR-CUL4B complex not mapped\", \"Physiological contexts where this dominates over transcription unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Mapped how AHR subcellular distribution is set, showing phosphorylation near NLS/NES and cell density control localization and target gene transactivation.\",\n      \"evidence\": \"Subcellular fractionation, live-cell imaging, NLS/NES mutagenesis, and phosphorylation studies\",\n      \"pmids\": [\"18983832\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Kinases acting on the NLS/NES not all identified\", \"Quantitative contribution relative to ligand-driven import unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified a non-canonical AHR signaling arm in which agonists drive MMP-1 expression through calcium/CaMKII/MAPK and AP-1 rather than XRE binding.\",\n      \"evidence\": \"Reporter assays, pharmacological inhibitors, and kinase activity assays in bronchial epithelial cells\",\n      \"pmids\": [\"24469321\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether AHR protein directly initiates the calcium signal is not established\", \"In vivo relevance to airway remodeling untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Provided evidence for ligand-independent activation, with PKA rendering AHR nuclear and activating target genes by a route distinct from exogenous ligand.\",\n      \"evidence\": \"PKA activation/inhibition studies and nuclear import assays\",\n      \"pmids\": [\"19013136\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single lab with limited mechanistic follow-up; molecular target of PKA on AHR not defined\", \"Physiological trigger for this mode unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated in vivo that CYP1A1 enzymes form a feedback loop depleting endogenous AHR ligands, linking AHR ligand availability to intestinal ILC3/Th17 immunity and infection resistance.\",\n      \"evidence\": \"Transgenic mice with constitutive or intestinal Cyp1a1, immune phenotyping, infection challenge, dietary rescue\",\n      \"pmids\": [\"28146477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the depleted endogenous ligands not fully defined\", \"Tissue-by-tissue ligand turnover not quantified\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Showed a ligand-independent, tumor-suppressive AHR function through direct interaction with Rb1 to restrain E2F-driven cell cycle progression.\",\n      \"evidence\": \"Overexpression/knockdown, AHR\\u2013Rb1 co-IP, and cell cycle analysis in pituitary GH3 cells\",\n      \"pmids\": [\"28649092\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal validation and structural basis of AHR\\u2013Rb1 binding lacking\", \"Generality beyond pituitary cells untested\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Linked AHR to myelin biology, showing AHR-deficient optic nerves have altered myelin lipid composition and reduced MAG with inflammation.\",\n      \"evidence\": \"Ahr-/- mice with lipid analysis, MAG immunostaining, and cytokine profiling\",\n      \"pmids\": [\"28851966\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AHR target genes driving myelination not identified\", \"Cell-autonomous versus inflammatory contributions not separated\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established AHR as a human disease gene, with a stop-gain mutation causing recessive foveal hypoplasia/nystagmus and mouse knockouts confirming a physiological role in optic nerve myelination.\",\n      \"evidence\": \"Whole exome sequencing in humans plus Ahr-/- mouse optic nerve histology\",\n      \"pmids\": [\"31009037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting AHR loss to foveal hypoplasia not defined\", \"Whether myelination defect explains the nystagmus fully unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Connected AHR loss to developmental endocrine phenotypes via Notch and ER\\u03b1 dysregulation in testis and mammary tissue.\",\n      \"evidence\": \"Ahr-/- mice with gene expression, histology, and serum hormone measurements\",\n      \"pmids\": [\"27688768\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect regulation of Notch genes not distinguished\", \"Relationship to the AHR-CUL4B/ER\\u03b1 degradation mechanism not integrated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified IL4I1 tryptophan catabolism as an endogenous source of AHR agonists driving tumor cell motility and immune suppression.\",\n      \"evidence\": \"Pan-tissue AHR signature, biochemical metabolite assays, and IL4I1-manipulated CLL mouse model\",\n      \"pmids\": [\"32818467\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of indoles versus kynurenic acid in vivo unclear\", \"Direct AHR target genes mediating motility not mapped\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined how AHR controls NK cell motility, transcriptionally inducing ASB2 to degrade filamin A and enable migration and tumor infiltration.\",\n      \"evidence\": \"Ahr-/- mice, AHR agonist treatment, ASB2 knockdown, and filamin A degradation/in vivo migration assays\",\n      \"pmids\": [\"33717133\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AHR binding at the ASB2 locus not shown\", \"Single lab without reciprocal genetic confirmation\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed AHR is required for aflatoxin B1 hepatotoxicity, with AFB1 binding the AHR N-terminus to drive nuclear translocation and P450 induction generating DNA adducts.\",\n      \"evidence\": \"Genome-wide CRISPR screen, AHR-knockout cells, adduct quantification, and translocation assays\",\n      \"pmids\": [\"34373448\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of N-terminal AFB1 binding not resolved\", \"Whether this differs from canonical PAS-B ligand engagement unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Implicated AHR in coronavirus infection, with viral activation of AHR and AHR inhibition suppressing HCoV-229E and SARS-CoV-2 replication.\",\n      \"evidence\": \"In vitro viral replication assays with AHR inhibitors and patient lung scRNA-seq\",\n      \"pmids\": [\"34446714\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which AHR signaling supports viral replication not defined\", \"Causality in patients inferred from expression only\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established a metabolic logic for AHR-driven keratinocyte differentiation: AHR represses glycolytic genes to raise SIRT1 in a pyruvate-dependent manner.\",\n      \"evidence\": \"ChIP, metabolic assays, protein measurements, and SIRT1 loss-of-function in keratinocytes\",\n      \"pmids\": [\"30393078\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct repression mechanism at SLC2A1/ENO1 versus indirect effects not fully separated\", \"In vivo skin relevance not tested in this study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Linked UVB-induced DNA damage to AHR-driven skin aging, showing AHR cooperates with SP1 to induce MMP2/MMP11 and that AHR antagonists reduce wrinkling.\",\n      \"evidence\": \"HaCaT mechanistic studies with AHR/SP1 inhibition, reporter assays, and a mouse wrinkle model\",\n      \"pmids\": [\"35316219\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AHR\\u2013SP1 promoter co-occupancy not structurally defined\", \"Selectivity for MMP2/MMP11 over MMP1/3 mechanistically unexplained\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided the structural basis of chaperone-held AHR, resolving the bridge motif inserting into Hsp90 and XAP2 stabilization of ligand-free PAS-B.\",\n      \"evidence\": \"Cryo-EM of Hsp90\\u2013AHR\\u2013p23 (\\u00b1XAP2) with mutagenesis\",\n      \"pmids\": [\"36649707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Conformational changes accompanying ligand binding and release not captured\", \"Structure of the active AHR\\u2013ARNT\\u2013DNA complex not resolved here\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined endothelial AHR as a sensor of dietary metabolites that maintains vascular quiescence and barrier integrity, protecting against influenza and enteric infection.\",\n      \"evidence\": \"Endothelial-specific AHR conditional knockouts, single-cell atlases, permeability assays, and infection challenge\",\n      \"pmids\": [\"37587341\", \"37586410\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific dietary ligands sensed in each vascular bed not fully identified\", \"Direct target genes downstream of apelin-APJ engagement not enumerated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed nutrient context tunes AHR sensitivity, with tryptophan deprivation inducing AHR and GCN2-dependent LAT1 to amplify kynurenine-driven AHR signaling and Treg differentiation.\",\n      \"evidence\": \"RT-qPCR, western blot, Ahr-variant and knockout T cells, and in vitro Treg differentiation\",\n      \"pmids\": [\"37344101\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of tryptophan-depletion-induced AHR overexpression not defined\", \"In vivo tumor relevance not directly tested here\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Connected AHR to macrophage-mediated immune suppression, showing AHR induces ALKAL1 to promote MerTK phosphorylation and immunosuppressive polarization.\",\n      \"evidence\": \"scRNA-seq, AHR antagonist studies, adoptive transfer, and targeted nanoparticle delivery in vivo\",\n      \"pmids\": [\"39365866\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AHR occupancy at ALKAL1 not shown\", \"Generalizability across tumor types not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How AHR integrates its canonical XRE-transcription, CUL4B-E3-ligase, and ligand-independent (Rb1/PKA) modes into a unified tissue-specific decision, and which endogenous ligands govern each context, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of the active AHR-ARNT-DNA complex in the timeline\", \"The endogenous ligand repertoire across tissues is incompletely defined\", \"Determinants selecting transcriptional versus E3-ligase output are unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 5, 11]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 5]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [3]},\n      {\"term_id\": \"GO:0140299\", \"supporting_discovery_ids\": [7, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 10, 22, 23]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [12, 19, 20]}\n    ],\n    \"complexes\": [\n      \"Hsp90\\u2013AHR\\u2013AIP/XAP2\\u2013p23 cytoplasmic chaperone complex\",\n      \"AHR\\u2013ARNT heterodimer\",\n      \"CUL4B^AHR E3 ubiquitin ligase\"\n    ],\n    \"partners\": [\n      \"ARNT\",\n      \"HSP90\",\n      \"AIP\",\n      \"p23\",\n      \"CUL4B\",\n      \"ESR1\",\n      \"AR\",\n      \"RB1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}